Madrigal Pharmaceuticals Inc (NAS:MDGL)
$ 229.58 -5.27 (-2.24%) Market Cap: 4.89 Bil Enterprise Value: 3.95 Bil PE Ratio: 0 PB Ratio: 5.58 GF Score: 44/100

Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call Transcript

Nov 16, 2021 / 01:00PM GMT
Release Date Price: $89.54 (-0.92%)
Operator

Good day, ladies and gentlemen, and welcome to the Madrigal Pharmaceuticals Resmetirom AASLD Clinical Data Review Conference Call. (Operator Instructions) As a reminder, this call may be recorded.

I would now like to introduce your host for today's conference, Dr. Paul Friedman, Chairman and Executive Officer of Madrigal. Dr. Friedman, you may begin.

Paul A. Friedman
Madrigal Pharmaceuticals, Inc. - Chairman & CEO

Thanks. Hello, and thanks for joining us on the call today. This is the fine print dealing with forward-looking statements we might make today. Please see our latest SEC filings for a summary of the risk factors associated with our business.

The primary purpose of the call is to review the latest data on resmetirom from the open-label portion of our ongoing Phase III MAESTRO-NAFLD-1 study, which was just presented at AASLD. Dr. Harrison will take us through these data, Dr. Stephen Harrison.

We're also entering an exciting period for Madrigal with the planned releases in the coming months of top line placebo-controlled

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot